Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive News from MarketBeat
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Author: Jeffrey Neal Johnson. Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite Dividend Kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
There are currently 200 paper claims for every 1 physical ounce of gold in the vaults - and a 90-year-old law set to 'call the bluff' on May 29th.
Dylan Jovine of Behind the Markets has identified a company sitting on $431 billion worth of metal that trades for a fraction of that value today. He calls it the 287-to-1 gap the market is about to correct. Run the numbers yourself - get the ticker and full analysis here
Abbott Laboratories’ stock price recently touched a 52-week low, closing just above $100 in the final trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott Laboratories’ situation shows a potential disconnect between market sentiment and operational reality. The key question for long-term investors is whether the market’s pessimism is justified or whether a meaningful value opportunity has emerged. Separating the Signal From the NoiseAbbott’s recent decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, driven largely by U.S. pediatric market-share losses and pricing dynamics that constrained volume. Management has acknowledged the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described pricing and promotional initiatives and a pipeline of at least eight new product launches in 2026 designed to reignite volume growth, with a return to growth expected in the second half of the year. The second factor is external and broader in scope. The market has been undergoing a significant capital rotation: in periods of greater economic optimism, investors have shifted money away from stable, defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in search of faster returns. That broad trend has pressured many fundamentally sound healthcare stocks, including Abbott, for reasons largely unrelated to their underlying businesses or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition navigates a short-term recovery, Abbott’s core businesses remain exceptionally strong, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model helps offset the isolated weakness in Nutrition, and the company’s strongest growth engines paint a clearer picture of its health.
Medical Devices: The Medical Devices business is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a growth phenomenon. The franchise, which lets users track glucose without routine fingersticks, generated over $7.5 billion in sales in 2025 and remains a primary driver of Abbott’s success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. That strength comes from a portfolio of best-in-class products—such as MitraClip and TriClip for minimally invasive valve repair—and a pipeline that includes the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also making a major strategic move to secure future growth through the acquisition of Exact Sciences, a leader in cancer screening and diagnostics best known for the non-invasive colon cancer test Cologuard. The deal would immediately strengthen Abbott’s position in the rapidly expanding, multi-billion-dollar cancer diagnostics market, adding a new, high-growth vertical that could contribute meaningfully to revenue for years to come. That bullish view is shared by professional analysts. Wall Street maintains a Moderate Buy consensus rating on the stock. The average 12-month price target sits at $135.47, implying potential upside of more than 30% from current levels and signaling that many analysts believe the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is one of the company’s most compelling attributes. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have raised their dividend for at least 50 consecutive years. That track record demonstrates a deep commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott’s stock price has a direct, positive effect for new investors: it increases the dividend yield. At current prices, Abbott offers a yield of roughly 2.5%, allowing investors to lock in a higher rate of income from this historically reliable payer. The dividend appears secure: the payout ratio is about 68% of earnings, and the dividend represents only about 37% of cash flow, indicating ample cash generation to cover payments and support future increases. A Disconnect Between Price and ValueThe market’s current view of Abbott appears disconnected from its operating reality. Temporary headwinds in a single division and a broad market rotation have depressed the stock price, yet Abbott’s fundamental growth engines are accelerating. Its dominant Medical Devices division continues to deliver, the dividend remains a reliable income stream, and strategic catalysts like the Exact Sciences acquisition loom on the horizon. For investors with a long-term horizon, the present valuation suggests a notable gap between price and intrinsic value—an opportunity worth serious consideration. |
